Project ID: BP-20240430-L-EE-82
Asthma: A Growing Global Health Concern
Asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways, leading to symptoms such as wheezing, shortness of breath, chest tightness, and coughing. The pathophysiology of asthma involves a complex interplay of genetic and environmental factors that trigger an immune response, resulting in airway hyperresponsiveness and inflammation. This inflammation causes the airways to become swollen and produce excess mucus, narrowing the airways and making it difficult to breathe.
Globally, asthma affects an estimated 358 million people, making it one of the most common chronic diseases worldwide. The prevalence of asthma has been increasing over the past few decades, with a significant impact on both individuals and healthcare systems.
The market for new asthma medications is substantial, driven by the need for more effective and safer treatments. The global asthma drugs market is projected to reach a value of approximately $40 billion by 2027, reflecting the ongoing demand for innovative therapies.
In terms of new drug developments, researchers and pharmaceutical companies are continuously working on novel approaches to treat asthma. These include monoclonal antibodies that target specific inflammatory pathways, biologics that modulate the immune response, and small molecule drugs that offer new mechanisms of action. Recent advancements have seen the introduction of drugs like Dupilumab, which targets the IL-4 and IL-13 pathways, and Lebrikizumab, which inhibits IL-13 signaling, offering new hope for patients with severe asthma.
The future of asthma treatment looks promising, with a pipeline of new drugs in various stages of clinical trials. These developments aim to provide more personalized and effective treatment options for the millions of people living with asthma around the world.
Request from MNC
Molecular Entities: Large Molecules, Small Molecules, RNA, In Vivo Cell Therapy
Current Stage: Preclinical, Phase I Clinical
Interest in Rights: Global Rights
Collaboration Model: License
How to Contact
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
